Vitamin D3 enhances the response to cisplatin in bladder cancer through VDR and TAp73 signaling crosstalk
Cancer Medicine: 10 April 2019 https://doi.org/10.1002/cam4.2119
Brittany L. Bunch Yingyu Ma Kristopher Attwood Lauren Amable Wei Luo Carl Morrison Khurshid A. Guru Anna Woloszynska‐Read … See all authors
- Urinary Bladder Cancer survival is associated with vitamin D receptor: 14 months vs 53 months – Oct 2015
- Bladder cancer modifiable risk factors include low vitamin D – meta-analysis March 2016
- Bladder cancer 60 percent less likely if have high vitamin D – meta-analysis Dec 2015
- Cancer - Bladder category listing has
28 items along with related searches - 51 diseases were strongly associated with Vitamin D Receptor as of March 2019
- Overview Cancer-Colon and vitamin D has the following Colon Cancer Prevention chart
Items in both categories Cancer - Bladder and Vitamin D Receptor are listed here:- Good Vitamin D receptor reduced bladder cancer and cisplatin deaths – April 2019
- Urinary Bladder Cancer survival is associated with vitamin D receptor: 14 months vs 53 months – Oct 2015
- Poor Bladder Cancer survival associated with poor Vitamin D receptor – Oct 2015
- Free vitamin D (VDR) may be more important than total for bladder cancer – March 2013
Chemotherapy and Cisplatin
- Chemotherapy (cisplatin) and vitamin D synergistically stop stomach cancer – Feb 2014
- Chemotheraphy not work as well with low Vitamin D (colon cancer this time) – Aug 2018
- Similar to the Bladder Cancer study on this page
- Chemotherapy and vitamin D - many studies cisplatin is mentioned several times
Items in both categories Vitamin D Receptor and Cancer
- 100 years since the discovery of Vitamin D - 23 studies - 2022, 2023
- Cancers are associated with low vitamin D, poor vaccination response and perhaps poor VDR – July 2022
- Poor prognosis of solid childhood cancers 14.7 X more likely with a poor Vitamin D Receptor – July 2022
- Cancers and Vitamin D Receptors, including change with race – Feb 2021
- Needing a high level of vitamin D is a good clue that the Vitamin D Receptor is deactivated
- Vitamin D Receptor (Cancers OR Viruses) - many studies
- Book: Sunlight, UV, Vitamin D and Receptor, Skin and other Cancers - Dec 2020
- How cancer is fought by Vitamin D (Ovarian this time) – Feb 2020
- 8 ways that Cancer might be prevented by Vitamin D - June 2019
- Cancer is leading cause of death - Vitamin D and Receptor activators help
- The Role of Resveratrol in Cancer Therapy – Dec 2017
- A poor Vitamin D Receptor is associated with many cancers (oral cancer in this case) – Jan 2019
- Overview of Vitamin D Actions in Cancer – 31 page chapter in a book – 2018
- Cancer treatment by Vitamin D sometimes is restricted by genes – Oct 2018
- Vitamin D receptor is essential for both normal and cancerous cells in the lab – June 2018
- Active Vitamin D reduces Ovarian Cancer stem cells growth by 4X (via Vitamin D receptor in lab rat) – March 2018
- Cancer and the Vitamin D Receptor, a primer – Sept 2017
- Cancer risks and Vitamin D Receptors – association is unclear – 2017
- Vitamin D, Vitamin D Receptor and Cancer – Nov 2016
- Risk of Cancer increased if poor Vitamin D Receptor – meta-analysis of 73 studies Jan 2016
- Role of Vitamin D in human Diseases and Disorders – An Overview – DBP, VDR June 2014
- Vitamin D Receptor role in Autoimmune Diseases and or cancers – Nov 2013
- Vitamin D receptor polymorphisms are risk factors for various cancers – meta-analysis Jan 2014
Vitamin D Receptor had the following - April 2019
Risk
increaseCancer 4.6 Breast Cancer 16.9 X another study 3.1 Colon Cancer survival 2.7 Gastric Cancer 2.4 Lung Cancer 1.6 Prostate Cancer while black
Vitamin D Receptor table shows what compensates for low VDR activation
Compensate for poor VDR by increasing one or more:Increasing Increases 1) Vitamin D supplement Sun
Ultraviolet -BVitamin D in the blood
and thus in the cells2) Magnesium Vitamin D in the blood
AND in the cells3) Omega-3 Vitamin D in the cells 4) Resveratrol Vitamin D Receptor 5) Intense exercise Vitamin D Receptor 6) Get prescription for VDR activator
paricalcitol, maxacalcitol?Vitamin D Receptor 7) Quercetin (flavonoid) Vitamin D Receptor 8) Zinc is in the VDR Vitamin D Receptor 9) Boron Vitamin D Receptor ?,
etc10) Essential oils e.g. ginger, curcumin Vitamin D Receptor 11) Progesterone Vitamin D Receptor 12) Infrequent high concentration Vitamin D
Increases the concentration gradientVitamin D Receptor 13) Sulfroaphane and perhaps sulfur Vitamin D Receptor 14) Butyrate especially gut Vitamin D Receptor 15) Berberine Vitamin D Receptor Note: If you are not feeling enough benefit from Vitamin D, you might try increasing VDR activation. You might feel the benefit within days of adding one or more of the above
Download the PDF from VitaminDWiki
Suspect that >20ng Vitamin D PLUS Good Vitamin D receptor would be even better
Background
Vitamin D3 (VitD) deficiency is linked to increased incidence and worse survival in bladder cancer (BCa). In addition to cystectomy, patients are treated with cisplatin‐based chemotherapy, however 30%‐50% of patients do not benefit from this treatment. The effects of VitD deficiency on response to chemotherapy remain unknown.Methods
To test effects of VitD supplementation on the response to cisplatin we analyzed patient serum VitD levels and correlated that with survival. In vivo, VitD deficient mice were treated with cisplatin, with or without pretreatment with the active VitD metabolite, 1,25 dihydroxyvitamin D3 (1,25D3). Lastly, using BCa cell lines, T24 and RT‐112, the mechanism of action of 1,25D3 and cisplatin combination treatment was determined by apoptosis assays, as well as western blot and RT‐PCR.Results
In this study, we determined that low serum 25 hydroxyvitamin D3 (25D3) levels was significantly associated with worse response to cisplatin. Pretreating deficient mice with 1,25D3, reduced tumor volume compared to cisplatin monotherapy. In vitro, 1,25D3 pretreatment increased the apoptotic response to cisplatin. 1,25D3 pretreatment increased expression of TAp73 and its pro‐apoptotic targets, in a VDR dependent manner. VDR and its transcriptional targets were induced after 1,25D3 treatment and further increased after the combination of 1,25D3 and cisplatin in a TAp73 dependent manner.Conclusions: Our data suggest that VitD deficiency could be a biomarker for poor response to cisplatin, and pretreating with VitD can increase the apoptotic response to cisplatin through VDR and TAp73 signaling crosstalk.
Printer Friendly Follow this page for updates5867 visitors, last modified 11 Apr, 2019,